Market Access News | pharmaphorum

News

Micrograph showing a small B-cell lymphoma compatible with follicular lymphoma

BeiGene breaks new ground for BTK drugs in blood cancers

BeiGene’s BTK inhibitor Brukinsa has become the first drug in the class to be approved in the US for follicular lymphoma, giving it the broadest label among its rivals.

News

UK access disparity resolved as NICE backs RCC therapy

Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab

News

NICE no follows Scottish aye for rare disease drug Xenpozyme

NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the U

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

News

Pharma’s Medicare counteroffers are all in, says HHS

On the heels of a setback in pharma’s legal attempts to block Medicare’s new medicine price negotiation powers, the US government has said all drugmakers whose products ar

News

NICE backs frontline use of Jemperli in endometrial cancer

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 w

BeiGene breaks new ground for BTK drugs in blood cancers

UK access disparity resolved as NICE backs RCC therapy

NICE no follows Scottish aye for rare disease drug Xenpozyme

Surprise Enhertu rejection follows NICE process change

Pharma’s Medicare counteroffers are all in, says HHS

NICE backs frontline use of Jemperli in endometrial cancer

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks